Travere Therapeutics Faces Setback as FDA Extends Filspari Review to April 13
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Should l Buy TVTX?
Source: NASDAQ.COM
- Regulatory Delay: The FDA has extended the review timeline for Travere Therapeutics' Filspari to April 13, three months later than the original January 13 deadline, resulting in a nearly 15% drop in stock price as investor confidence waned.
- Significant Drug Potential: Filspari targets focal segmental glomerulosclerosis (FSGS), and if approved, it would be the first FDA-approved drug for this condition, leading to high market expectations for its success.
- Overreaction in the Market: Although delays due to 'major amendments' are common with the FDA, the market's reaction to this news appears excessive, with analysts believing that Travere still holds substantial potential for this new indication of Filspari.
- Clinical Benefit Assessment: Travere stated in its press release that the extension is to further characterize the clinical benefits of Filspari, demonstrating the company's confidence and commitment to the drug's success.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 30.600
Low
31.00
Averages
42.89
High
49.00
Current: 30.600
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Travere Grants Equity Inducements to New Employees
- Equity Incentive Program: On February 10, 2026, Travere Therapeutics granted 49,200 restricted stock units (RSUs) to ten new employees, highlighting the company's commitment to attracting talent and enhancing its workforce.
- Grant Conditions: These RSUs were awarded outside of the 2018 Equity Incentive Plan but comply with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's flexibility in incentivizing new hires.
- Vesting Arrangement: The RSUs vest over four years with 25% vesting annually, which not only encourages long-term retention of new employees but also strengthens team stability and cohesion.
- Company Mission: Travere is dedicated to providing treatment options for rare disease patients, emphasizing its mission in the biopharmaceutical sector to improve patient lives through innovative therapies, thereby reinforcing its market position.
See More
Travere Grants Inducement Equity to New Employees
- Equity Incentive Plan: On February 10, 2026, Travere Therapeutics granted inducement restricted stock units (RSUs) covering 49,200 shares to ten new employees, aimed at attracting talent and enhancing employee loyalty.
- Grant Conditions: These RSUs were granted outside of Travere's 2018 Equity Incentive Plan but comply with Nasdaq Listing Rule 5635(c)(4), serving as inducements for new hires.
- Vesting Arrangement: The RSUs vest over four years with 25% vesting annually, ensuring continued service from new employees while enhancing talent retention within the company.
- Company Mission: Travere is committed to providing treatment options for rare disease patients, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, reflecting the company's deep care for patients.
See More
Travere Therapeutics to Present at Guggenheim Biotech Summit 2026
- Event Announcement: Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 4:00 p.m. ET, showcasing the company's latest advancements in the rare disease sector.
- Live Webcast: The presentation will be accessible via a live webcast on Travere's investor page at ir.travere.com/events-and-presentations, with a replay available for 30 days post-event, ensuring that investors unable to attend live can still access the information.
- Company Mission: Travere Therapeutics focuses on providing urgently needed treatment options for patients with rare diseases and their families, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, reflecting the company's commitment to patient needs.
- Future Outlook: By participating in this summit, Travere aims to enhance its influence in the biopharmaceutical industry, demonstrating its innovative efforts in rare disease treatment and boosting investor confidence in the company's future growth.
See More
Investigation into Potential Securities Violations at Travere Therapeutics
- Investigation Background: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics, Inc., focusing on whether the company and its executives made materially false or misleading statements or omitted critical information that could harm investors.
- Investor Call to Action: The firm is urging any Travere investors with relevant information, particularly those who have suffered losses, to come forward to assist in the investigation and pursue potential compensation for their losses.
- Company Overview: Travere Therapeutics is a biopharmaceutical company dedicated to developing therapies for rare kidney and metabolic diseases, primarily serving the U.S. market, highlighting its specialization and the demand in this niche medical field.
- Law Firm's Strength: Robbins Geller is one of the world's leading law firms in securities fraud and shareholder litigation, having been ranked #1 in ISS Securities Class Action Services for four out of the last five years, recovering over $2.5 billion for investors in 2024 alone, underscoring its significant influence in the industry.
See More
Robbins Geller Investigates Potential Securities Violations by Travere Therapeutics
- Investigation Launched: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics (NASDAQ: TVTX), focusing on whether executives made materially false or misleading statements that could undermine investor confidence.
- Investor Loss Focus: The investigation particularly targets investors who suffered losses in Travere, with the firm encouraging affected individuals to provide information, demonstrating a commitment to protecting investor rights.
- Law Firm Strength: Robbins Geller is recognized as one of the world's leading law firms in securities fraud and shareholder litigation, having ranked #1 in ISS Securities Class Action Services for four out of the last five years, highlighting its strong capability in securing investor compensation.
- Historical Recovery Record: In 2024, the firm recovered over $2.5 billion for investors in securities-related class action cases, surpassing the combined total of the next five law firms, showcasing its exceptional performance in the securities litigation arena.
See More
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Market Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing robust market demand for its products.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, driving total revenue up from $62.9 million to $164.9 million, highlighting its strong performance in the rare disease treatment sector.
- FDA Review Catalyst: The ongoing FDA review of Travere's FILSPARI for potential use in treating focal segmental glomerulosclerosis has heightened market expectations for the company, further bolstering Palisades' investment confidence.
See More
Travere Grants Equity Inducements to New Employees
- Equity Incentive Program: On February 10, 2026, Travere Therapeutics granted 49,200 restricted stock units (RSUs) to ten new employees, highlighting the company's commitment to attracting talent and enhancing its workforce.
- Grant Conditions: These RSUs were awarded outside of the 2018 Equity Incentive Plan but comply with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's flexibility in incentivizing new hires.
- Vesting Arrangement: The RSUs vest over four years with 25% vesting annually, which not only encourages long-term retention of new employees but also strengthens team stability and cohesion.
- Company Mission: Travere is dedicated to providing treatment options for rare disease patients, emphasizing its mission in the biopharmaceutical sector to improve patient lives through innovative therapies, thereby reinforcing its market position.
See More
Travere Grants Inducement Equity to New Employees
- Equity Incentive Plan: On February 10, 2026, Travere Therapeutics granted inducement restricted stock units (RSUs) covering 49,200 shares to ten new employees, aimed at attracting talent and enhancing employee loyalty.
- Grant Conditions: These RSUs were granted outside of Travere's 2018 Equity Incentive Plan but comply with Nasdaq Listing Rule 5635(c)(4), serving as inducements for new hires.
- Vesting Arrangement: The RSUs vest over four years with 25% vesting annually, ensuring continued service from new employees while enhancing talent retention within the company.
- Company Mission: Travere is committed to providing treatment options for rare disease patients, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, reflecting the company's deep care for patients.
See More
Travere Therapeutics to Present at Guggenheim Biotech Summit 2026
- Event Announcement: Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 4:00 p.m. ET, showcasing the company's latest advancements in the rare disease sector.
- Live Webcast: The presentation will be accessible via a live webcast on Travere's investor page at ir.travere.com/events-and-presentations, with a replay available for 30 days post-event, ensuring that investors unable to attend live can still access the information.
- Company Mission: Travere Therapeutics focuses on providing urgently needed treatment options for patients with rare diseases and their families, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, reflecting the company's commitment to patient needs.
- Future Outlook: By participating in this summit, Travere aims to enhance its influence in the biopharmaceutical industry, demonstrating its innovative efforts in rare disease treatment and boosting investor confidence in the company's future growth.
See More
Investigation into Potential Securities Violations at Travere Therapeutics
- Investigation Background: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics, Inc., focusing on whether the company and its executives made materially false or misleading statements or omitted critical information that could harm investors.
- Investor Call to Action: The firm is urging any Travere investors with relevant information, particularly those who have suffered losses, to come forward to assist in the investigation and pursue potential compensation for their losses.
- Company Overview: Travere Therapeutics is a biopharmaceutical company dedicated to developing therapies for rare kidney and metabolic diseases, primarily serving the U.S. market, highlighting its specialization and the demand in this niche medical field.
- Law Firm's Strength: Robbins Geller is one of the world's leading law firms in securities fraud and shareholder litigation, having been ranked #1 in ISS Securities Class Action Services for four out of the last five years, recovering over $2.5 billion for investors in 2024 alone, underscoring its significant influence in the industry.
See More
Robbins Geller Investigates Potential Securities Violations by Travere Therapeutics
- Investigation Launched: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics (NASDAQ: TVTX), focusing on whether executives made materially false or misleading statements that could undermine investor confidence.
- Investor Loss Focus: The investigation particularly targets investors who suffered losses in Travere, with the firm encouraging affected individuals to provide information, demonstrating a commitment to protecting investor rights.
- Law Firm Strength: Robbins Geller is recognized as one of the world's leading law firms in securities fraud and shareholder litigation, having ranked #1 in ISS Securities Class Action Services for four out of the last five years, highlighting its strong capability in securing investor compensation.
- Historical Recovery Record: In 2024, the firm recovered over $2.5 billion for investors in securities-related class action cases, surpassing the combined total of the next five law firms, showcasing its exceptional performance in the securities litigation arena.
See More
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Market Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing robust market demand for its products.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, driving total revenue up from $62.9 million to $164.9 million, highlighting its strong performance in the rare disease treatment sector.
- FDA Review Catalyst: The ongoing FDA review of Travere's FILSPARI for potential use in treating focal segmental glomerulosclerosis has heightened market expectations for the company, further bolstering Palisades' investment confidence.
See More
